Palatin’s stock plummets 43% as lead asset fails PhIII dry eye co-primary endpoints
Although Palatin Technologies’ lead drug candidate missed a pair of primary endpoints in a Phase III dry eye disease trial, the company believes there’s still …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
